Blagojevic Jelena, Matucci-Cerinic Marco
Department of Biomedicine, Reference Center for Systemic Sclerosis, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
Nat Clin Pract Rheumatol. 2009 Feb;5(2):70-1. doi: 10.1038/ncprheum0993.
Research suggests that statins could be useful to treat vascular manifestations related to systemic sclerosis, but data on their potential clinical benefits remain limited. Previous studies suggested that statins increase the number of circulating endothelial precursor cells, and thereby improve the severity of Raynaud's phenomenon. Abou-Raya et al. have published the first randomized, double-blind, placebo-controlled clinical trial on the effect of statins on clinical outcomes in the vascular manifestations of systemic sclerosis. They observed significant reductions in the overall number of digital ulcers and in the mean number of new digital ulcers per patient in the statin group. In addition, statin-treated patients experienced significant improvements in disability scores and functional status. The data from this study indicate that statins might improve endothelial function, thereby contributing to clinical, functional recovery. These results pave the way for large studies on the use of statins in vascular complications related to systemic sclerosis.
研究表明，他汀类药物可能有助于治疗与系统性硬化症相关的血管表现，但关于其潜在临床益处的数据仍然有限。先前的研究表明，他汀类药物可增加循环内皮祖细胞的数量，从而改善雷诺现象的严重程度。阿布-拉亚等人发表了第一项关于他汀类药物对系统性硬化症血管表现临床结局影响的随机、双盲、安慰剂对照临床试验。他们观察到他汀类药物组患者的指端溃疡总数和每位患者新出现的指端溃疡平均数量显著减少。此外，接受他汀类药物治疗的患者在残疾评分和功能状态方面有显著改善。这项研究的数据表明，他汀类药物可能改善内皮功能，从而促进临床和功能恢复。这些结果为关于他汀类药物在与系统性硬化症相关的血管并发症中的应用的大型研究铺平了道路。
